Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
A significant proportion of treatment-experienced hepatitis C virus genotype 1 (GT1) patients will not achieve sustained virologic response [corrected] with protease inhibitor-triple therapy, and so the need for alternative therapies for these patients remains high. The aim of this article is to provide a critical evaluation of the available data, highlighting the knowledge gaps and providing a practical framework for making treatment decisions in treatment-experienced GT1 patients with currently approved drugs.
Department of Medicine, Viral Hepatitis Center, University of California San Francisco, Room S-357, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Jennifer A
JA
Flemming
Norah A
NA
Terrault
D000998:Antiviral Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects; D011392:Proline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000008:administration & dosage; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects; D019562:Viral Load / Q000187:drug effects
D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; D012367:RNA, Viral; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D007372:Interferons; D011392:Proline